Ernexa Therapeutics (ERNAW) Tax Provisions (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Tax Provisions data on file, last reported at -$40000.0 in Q1 2026.

• Quarterly Tax Provisions fell 600.0% year-over-year to -$40000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$93000.0 (down 1428.57% YoY) and the FY2025 annual result came in at -$45000.0, down 1600.0% from the prior year.
• Tax Provisions improved to -$40000.0 in Q1 2026, from -$62000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $40000.0 in Q4 2022 to a low of -$62000.0 in Q4 2025.
• A 5-year average of -$2666.7 and a median of $4000.0 in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2024 — Tax Provisions jumped 250.0% — and 2026, when it tumbled 600.0%.
• Tracing ERNAW's Tax Provisions over 5 years: stood at $40000.0 in 2022, then tumbled by 110.0% to -$4000.0 in 2023, then slumped by 300.0% to -$16000.0 in 2024, then tumbled by 287.5% to -$62000.0 in 2025, then soared by 35.48% to -$40000.0 in 2026.
• The last three Tax Provisions figures came in at -$40000.0 (Q1 2026), -$62000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.